Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2018 Apr 20

PMID 29670046

Citations 168

Authors

Yoshiro Itatani

Kenji Kawada

Takamasa Yamamoto

Yoshiharu Sakai

Affiliations

Soon will be listed here.

Abstract

Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic colorectal cancer (CRC) by the Food and Drug Administration (FDA) in 2004. In addition, the other VEGF pathway inhibitors including small molecule tyrosine kinase inhibitors (sunitinib, sorafenib, and pazopanib), a soluble VEGF decoy receptor (aflibercept), and a humanized monoclonal antibody of VEGF receptor 2 (VEGFR2) (ramucirumab) have been approved for cancer therapy. Although many types of VEGF pathway inhibitors can improve survival in most cancer patients, some patients have little or no beneficial effect from them. The primary or acquired resistance towards many oncological drugs, including anti-VEGF inhibitors, is a common problem in cancer treatment. This review summarizes the proposed alternative mechanisms of angiogenesis other than the VEGF pathway. These mechanisms are involved in the development of resistance to anti-VEGF therapies in cancer patients.

Citing Articles

Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy.

Jiao J, Wu Y, Wu S, Jiang J Curr Treat Options Oncol. 2025; .

PMID: 40045029 DOI: 10.1007/s11864-025-01306-8.

Real-World Evidence of Bevacizumab and Panitumumab Drug Resistance and Drug Ineffectiveness from EudraVigilance Database.

Vonica R, Morgovan C, Butuca A, Pumnea M, Cipaian R, Frum A Cancers (Basel). 2025; 17(4).

PMID: 40002260 PMC: 11853327. DOI: 10.3390/cancers17040663.

Critical roles of miR-21 in promotions angiogenesis: friend or foe?.

Saadh M, Jasim N, Ahmed M, Ballal S, Kumar A, Atteri S Clin Exp Med. 2025; 25(1):66.

PMID: 39998742 PMC: 11861128. DOI: 10.1007/s10238-025-01600-7.

Cancer-secreted exosomal miR-1825 induces angiogenesis to promote colorectal cancer metastasis.

Sun J, Luo J, Liu J, Wu H, Li Y, Xu Y Cancer Cell Int. 2025; 25(1):63.

PMID: 39987450 PMC: 11847347. DOI: 10.1186/s12935-025-03674-5.

Decoding oral cancer: insights from miRNA expression profiles and their regulatory targets.

Wang X, Zhang S, Wang S, Cao T, Fan H Front Mol Biosci. 2025; 11:1521839.

PMID: 39935706 PMC: 11810738. DOI: 10.3389/fmolb.2024.1521839.

References

Heldin C . Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal. 2013; 11:97. PMC: 3878225. DOI: 10.1186/1478-811X-11-97. View

Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R . Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005; 353(25):2654-66. DOI: 10.1056/NEJMoa051424. View

Casanovas O, Hicklin D, Bergers G, Hanahan D . Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8(4):299-309. DOI: 10.1016/j.ccr.2005.09.005. View

Fischer C, Mazzone M, Jonckx B, Carmeliet P . FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat Rev Cancer. 2008; 8(12):942-56. DOI: 10.1038/nrc2524. View

Lassen U, Chinot O, McBain C, Mau-Sorensen M, Larsen V, Barrie M . Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro Oncol. 2015; 17(7):1007-15. PMC: 5654352. DOI: 10.1093/neuonc/nov019. View

Kuusk T, Albiges L, Escudier B, Grivas N, Haanen J, Powles T . Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. Angiogenesis. 2017; 20(2):205-215. DOI: 10.1007/s10456-017-9550-0. View

Rock E, Goodman V, Jiang J, Mahjoob K, Verbois S, Morse D . Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007; 12(1):107-13. DOI: 10.1634/theoncologist.12-1-107. View

Soker S, Takashima S, Miao H, Neufeld G, Klagsbrun M . Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998; 92(6):735-45. DOI: 10.1016/s0092-8674(00)81402-6. View

Poon R, Fan S, Wong J . Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001; 19(4):1207-25. DOI: 10.1200/JCO.2001.19.4.1207. View

10.

Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky T . Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer. 2010; 103(9):1407-14. PMC: 2990609. DOI: 10.1038/sj.bjc.6605925. View

11.

Ebos J, Lee C, Cruz-Munoz W, Bjarnason G, Christensen J, Kerbel R . Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15(3):232-9. PMC: 4540346. DOI: 10.1016/j.ccr.2009.01.021. View

12.

Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L . Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007; 131(3):463-75. DOI: 10.1016/j.cell.2007.08.038. View

13.

Kopetz S, Hoff P, Morris J, Wolff R, Eng C, Glover K . Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2009; 28(3):453-9. PMC: 2815707. DOI: 10.1200/JCO.2009.24.8252. View

14.

Phan V, Wu X, Cheng J, Sheng R, Chung A, Zhuang G . Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci U S A. 2013; 110(15):6079-84. PMC: 3625253. DOI: 10.1073/pnas.1303302110. View

15.

Andre F, Bachelot T, Campone M, Dalenc F, Perez-Garcia J, Hurvitz S . Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013; 19(13):3693-702. DOI: 10.1158/1078-0432.CCR-13-0190. View

16.

Carbone C, Piro G, Simionato F, Ligorio F, Cremolini C, Loupakis F . Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. Clin Cancer Res. 2017; 23(15):4312-4322. DOI: 10.1158/1078-0432.CCR-16-3153. View

17.

Tchaicha J, Reyes S, Shin J, Hossain M, Lang F, McCarty J . Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by β8 integrin. Cancer Res. 2011; 71(20):6371-81. PMC: 3193578. DOI: 10.1158/0008-5472.CAN-11-0991. View

18.

Avraamides C, Garmy-Susini B, Varner J . Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008; 8(8):604-17. PMC: 2577722. DOI: 10.1038/nrc2353. View

19.

Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, Beug H . Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res. 2004; 566(1):9-20. DOI: 10.1016/s1383-5742(03)00033-4. View

20.

Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, de Mol M . Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001; 7(5):575-83. DOI: 10.1038/87904. View